$SRRK

Burow Kristina sold $164K of SRRK

Burow Kristina sold 3,053 shares of Scholar Rock Holding Corp (SRRK) at an average of $53.74 ($53.49–$54.28, $0.16M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Burow Kristina
Published Jul 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SRRK
Neutral
medium confidence
Mentioned
$SRRK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRRKNeutralLow
01

Why it matters

The disclosure updates the record of insider activity and may influence short-term sentiment, but it does not introduce new fundamentals.

02

Market read

A director’s scheduled insider sale is disclosed, which can slightly affect sentiment but is unlikely to drive a fundamental repricing by itself.

03

What to watch

Traders may overreact to insider selling; the key nuance here is the pre-arranged 10b5-1 structure and the lack of any accompanying company-specific news.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-06 for trades dated 2026-07-01

Background

The article is an SEC Form 4 insider transaction disclosure for Scholar Rock Holding Corp, reported by a director.

Company-level read

Ticker impact

$SRRKNeutralMedium confidence
Context

Scholar Rock director Kristina Burow sold about 3,053 shares in open-market trades under a 10b5-1 plan, totaling $164,063.83.

Expected impact

Likely limited near-term impact; any effect is more about optics than new company information.

Evidence & confidence

The filing discloses the transaction size and timing, but provides no new operational, financial, or regulatory facts about Scholar Rock.

Market effects

No clear sector read-through from a single director 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations, reducing the signal value.

Key entities

  • Scholar Rock Holding Corp

    Subject of the Form 4 insider transaction disclosure.

  • Kristina Burow

    Director who executed open-market sales under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IONSHighAI 8/10

FDA Drug Approvals In September 2026

The FDA approved 13 drugs in September 2026, including Zanvastro (IONS) for Alexander disease, Omcazio (6620.TWO) for various cancers, Etcamah (AZN) for breast cancer, Pixclara (TLX) for glioma diagnosis, and ISEMBLYD (SRRK) for SMA. Key pricing and clinical data were reported.

$SRRKMed

Raymond James reiterates Scholar Rock stock rating on MAA resubmission

Raymond James reiterated a Strong Buy rating and $72.00 price target for Scholar Rock (SRRK) after its MAA resubmission for apitegromab in the EU. The stock trades at $41.99, down 8.6% in a week, with a $5.08B market cap. The company expects a regulatory opinion in early 2027. Analysts highlight the potential for significant non-U.S. revenue, with estimates ranging from $2.2B to $3.1B by 2035.

$SRRKMed

Scholar Rock Revives European Filing For SMA Therapy After U.S. Approval

Scholar Rock (SRRK) resubmitted its European application for apitegromab, a treatment for spinal muscular atrophy (SMA), after addressing a manufacturing issue. The resubmission includes a new facility and is supported by Phase 3 trial results showing motor function improvements. The EMA is expected to issue an opinion in 2027. SRRK shares are currently trading at $41.48, down 1.71%.

$SRRKMed

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

Scholar Rock (SRRK) resubmitted its Marketing Authorisation Application (MAA) for apitegromab to the European Medicines Agency (EMA) for treating spinal muscular atrophy (SMA). The resubmission includes an alternate fill-finish facility, aligning with EMA guidance. The company anticipates a CHMP opinion in H1 2027. Apitegromab, marketed as ISEMBYLD in the U.S., is the first muscle-targeted therapy to show motor function improvement in SMA patients.